Washington, DC 20006-5349
HELPLINE
Mesothelioma in and of itself is a misunderstood diagnosis. As a cancer that affects roughly 3,000 Americans per year, it is often mistakenly thought of…
Last week, the Polaris Group announced positive results of its Phase 2/3 clinical trial evaluating the effectiveness of an arginine degrading enzyme agent called ADI-PEG 20.…
The Mesothelioma Applied Research Foundation is proud to announce the recipients of its most recent round of new mesothelioma research funding. Through a rigorous review…
This week, the paper “Medical and surgical care of mesothelioma patients and their relatives carrying germline BAP1 mutations,” by Drs. Michele Carbone, Harvey Pass, and…
Data from a study comparing the efficacy of anetumab ravtansine, a monoclonal antibody conjugate, against vinorelbine showed no improvement in progression-free survival. The results of…
“We are at a point where in the next few years we’re going to have a lot more options for our patients,” said Dr. Hedy…
The field of radiology and imaging has relatively quickly advanced from simple x-rays that allow us to take a non-invasive, albeit limited, peek inside the…
As 2021 concludes and 2022 begins, we bring you mesothelioma treatment news directly from clinicians and researchers. Two newly published articles give us a useful…
This week, Nature Medicine published the results, as well the genomic and immunologic analyses, from the Phase 2 PrE0505 clinical trial. The trial, which took…
Jessica Blackford-Cleeton and Rich Mosca, both members of the mesothelioma community, recently participated in the evaluation of research proposals for funding through the Congressionally Directed…
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
